156 related articles for article (PubMed ID: 33979008)
1. The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study.
Bharat C; Larney S; Barbieri S; Dobbins T; Jones NR; Hickman M; Gisev N; Ali R; Degenhardt L
Addiction; 2021 Nov; 116(11):3139-3152. PubMed ID: 33979008
[TBL] [Abstract][Full Text] [Related]
2. Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.
Jones NR; Nielsen S; Farrell M; Ali R; Gill A; Larney S; Degenhardt L
Drug Alcohol Depend; 2021 Feb; 219():108464. PubMed ID: 33360851
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
[TBL] [Abstract][Full Text] [Related]
4. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
[TBL] [Abstract][Full Text] [Related]
5. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
6. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
7. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention.
Burns L; Randall D; Hall WD; Law M; Butler T; Bell J; Degenhardt L
Addiction; 2009 Aug; 104(8):1363-72. PubMed ID: 19549053
[TBL] [Abstract][Full Text] [Related]
8. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
[TBL] [Abstract][Full Text] [Related]
9. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
10. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
11. Opioid agonist treatment for pharmaceutical opioid dependent people.
Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
[TBL] [Abstract][Full Text] [Related]
12. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study.
Gisev N; Bharat C; Larney S; Dobbins T; Weatherburn D; Hickman M; Farrell M; Degenhardt L
Lancet Public Health; 2019 Jul; 4(7):e334-e342. PubMed ID: 31201133
[TBL] [Abstract][Full Text] [Related]
13. Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.
Jones NR; Shanahan M; Dobbins T; Degenhardt L; Montebello M; Gisev N; Larney S
Drug Alcohol Rev; 2019 Sep; 38(6):690-698. PubMed ID: 31577058
[TBL] [Abstract][Full Text] [Related]
14. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
15. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
Bell J; Trinh L; Butler B; Randall D; Rubin G
Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
[TBL] [Abstract][Full Text] [Related]
16. Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment.
Bharat C; Degenhardt L; Dobbins T; Larney S; Farrell M; Barbieri S
Drug Alcohol Depend; 2021 Nov; 228():109091. PubMed ID: 34592705
[TBL] [Abstract][Full Text] [Related]
17. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study.
Kimber J; Larney S; Hickman M; Randall D; Degenhardt L
Lancet Psychiatry; 2015 Oct; 2(10):901-8. PubMed ID: 26384619
[TBL] [Abstract][Full Text] [Related]
18. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
19. Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia.
Chaillon A; Bharat C; Stone J; Jones N; Degenhardt L; Larney S; Farrell M; Vickerman P; Hickman M; Martin NK; Bórquez A
Addiction; 2022 May; 117(5):1338-1352. PubMed ID: 34729841
[TBL] [Abstract][Full Text] [Related]
20. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
